A Kent and Medway Cancer Network (KMCN) audit of first-line treatment with cisplatin/pemetrexed (CisPem) in non squamous non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Letsa, I. [1 ]
Mikropoulos, C. [1 ]
Burcombe, R. [1 ]
Visioli, A. [1 ]
Sevitt, T. [1 ]
Cominos, M. [1 ]
Beesley, S. [1 ]
机构：
[1] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
来源：
LUNG CANCER | 2011年 / 71卷
关键词：
D O I：
10.1016/S0169-5002(11)70019-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [1] A Kent and Medway Cancer Network (KMCN) audit of second-line treatment for non-small cell lung cancer
    Cafferkey, C.
    Jamal-Hanjani, M.
    Beesley, S.
    Cominos, M.
    Sevitt, T.
    Taylor, H.
    Burcombe, R.
    Shah, R.
    LUNG CANCER, 2010, 67 : S7 - S8
  • [2] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [3] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
    Silva, S.
    Colquitt, J.
    Hatton, M. Q.
    Mohanamurali, J.
    Lee, C.
    Danson, S.
    Fisher, P.
    Woll, P.
    LUNG CANCER, 2014, 83 : S13 - S13
  • [4] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [5] PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Megaiz, Ahlem
    Bousahba, Abdelkader
    Rabah, Aicha
    Zemmour, Amel
    Ahed-Messaoud, Malika
    Ghazli, Soumia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S588 - S589
  • [6] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
  • [7] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [8] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [10] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
12345